A LEF1/β-catenin inhibitor, CGP049090, and PFK115-584 decreased the expression of CTNNB1/LEF1 target genes c-myc, cyclin D1, and survivin in AML cell lines Kasumi-1 and HL-60 [141]. Here, LEF1 is linked to acute myeloid leukemia.